Biomarker analysis in Phase 1b study of anti-cancer stem cell antibody Tarextumab (TAR) in combination with nab-paclitaxel and gemcitabine (Nab-P plus Gem) demonstrates pharmacodynamic (PD) modulation of the Notch pathway in patients (pts) with untreated metastatic pancreatic cancer (mPC)

被引：0
|
作者：
Kapoun, A. [1 ]
O'Reilly, E. [2 ]
Cohn, A. [3 ]
Bendell, J. C. [4 ]
Smith, L. [5 ]
Strickler, J. H. [6 ]
Gluck, W. [7 ]
Liu, Y. W. [1 ]
Wallace, B. [1 ]
Tam, R. [1 ]
Cancilla, B. [1 ]
Brunner, A. [1 ]
Hill, D. [1 ]
Zhou, L. [1 ]
Dupont, J. [1 ]
Zhang, C. [1 ]
Wang, M. [1 ]
机构：
[1] OncoMed Pharmaceut, Davis, CA USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY USA
[3] Rocky Mt Canc Ctr, Denver, CO USA
[4] Sarah Canon Res Inst, Nashville, TN USA
[5] START, San Antonio, TX USA
[6] Duke Univ, Durham, NC USA
[7] Greenville Hosp Syst, Greenville, SC USA
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
10.1016/S0959-8049(14)70591-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
465
引用
收藏
页码：152 / 152
页数：1
相关论文
共 50 条
  • [31] A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study
    Cohen, Steven J.
    O'Neil, Bert H.
    Berlin, Jordan
    Ames, Patricia
    McKinley, Marti
    Horan, Julie
    Catalano, Patricia M.
    Davies, Angela
    Weekes, Colin D.
    Leichman, Lawrence
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 693 - 701
  • [32] A phase 1b study of the anticancer stem cell agent demcizumab (DEM) and gemcitabine (GEM) with or without paclitaxel protein bound particles (nab-paclitaxel) in patients with pancreatic cancer
    Gracian, Antonio Cubillo
    Jameson, Michael B.
    Grande, Enrique
    Cooray, Prasad
    Parnis, Francis
    Grimison, Peter
    Jeffery, Mark
    Stagg, Robert J.
    Dupont, Jakob
    Tebbutt, Niall C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [33] Phase 1 study of anti-immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482+pembrolizumab plus gemcitabine plus nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Golan, Talia
    Cohen, Jonathan
    Voskoboynik, Mark
    Gutierrez, Martin
    Park, John J.
    Valente, Monica
    Renouf, Daniel John
    Liu, Qi
    Edmondson, Mackenzie
    Myer, Nicole
    Kapadia, Kishan J.
    Chen, Mei
    Victoria, Ivan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [34] A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
    Shahda, Safi
    El-Rayes, Bassel F.
    O'Neil, Bert H.
    Starodub, Alexander
    Hanna, Wahid Tewfik
    Borodyansky, Laura
    Oh, Cindy
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [35] Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) plus nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
    Bekaii-Saab, Tanios S.
    Starodub, Alexander
    El-Rayes, Bassel F.
    Shahda, Safi
    O'Neil, Bert H.
    Noonan, Anne M.
    Shaib, Walid Labib
    Hanna, Wahid Tewfik
    Mikhail, Sameh
    Neki, Anterpreet S.
    Chang, Yue
    Dai, Xiaoshu
    Li, Wei
    Brooks, Emily
    Oh, Cindy
    Borodyansky, Laura
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [36] Phase II study of nab-paclitaxel/gemcitabine (NabP-Gem) alternating with FOLFIRI as 1st line therapy (Rx) in patients (pts) with metastatic pancreatic cancer (mPC).
    Picozzi, Vincent J.
    Leach, Joseph
    Larson, Tim
    Nishikubo, Carol Y.
    Anthony, Stephen Patrick
    Lin, Bruce S.
    Bolejack, Vanessa
    Stoll, Amy C.
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] nab-Paclitaxel (nab-P) plus gemcitabine (Gem) for patients with advanced pancreatic cancer who have cholestatic hyperbilirubinemia (CH) secondary to bile duct obstruction: a phase I safety and pharmacokinetics study
    Riess, H.
    Kunzmann, V.
    Philip, P.
    Seufferlein, T.
    McGovern, D.
    Chen, P.
    Romano, A.
    Ramanathan, R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [38] [18F]2-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) response and survival analysis in a phase 1/2 trial of nab-paclitaxel (nab-P) plus gemcitabine (gem) for metastatic pancreatic cancer (MPC)
    Ramanathan, R.
    Von Hoff, D.
    Borad, M.
    Li, J. Shiansong
    McGovern, D.
    Renschler, M.
    Korn, R.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S118 - S118
  • [39] Efficacy, Safety and Pharmacokinetics (PK) of Weekly nab-paclitaxel (P) Plus Gemcitabine (G) in Japanese Patients (pts) With Metastatic Pancreatic Cancer (MPC): Phase I/II Trial
    Kasuga, A.
    Ueno, H.
    Ikeda, M.
    Ueno, M.
    Mizuno, N.
    Ioka, T.
    Omuro, Y.
    Nakajima, T. E.
    Furuse, J.
    PANCREAS, 2014, 43 (08) : 1374 - 1374
  • [40] Nab-paclitaxel (Nab-P) and gemcitabine (G) first-line chemotherapy (CT) in patients (pts) with metastatic pancreatic cancer (mPC) who relapsed after adjuvant treatment (ADJ T): A "REAL LIFE" study.
    Giordano, Guido
    Milella, Michele
    Lo Re, Giovanni
    Di Marco, Mariacristina
    Melisi, Davide
    Passardi, Alessandro
    Febbraro, Antonio
    Iop, Aldo
    Vaccaro, Vanja
    Foltran, Luisa
    Bertocchi, Paola
    Bergamo, Francesca
    Vecchiarelli, Silvia
    Giommoni, Elisa
    Ricci, Vincenzo
    Aloi, Maria Bernardetta
    Vasile, Enrico
    Zaniboni, Alberto
    Zagonel, Vittorina
    De Vita, Ferdinando
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345